索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 研究圣经
  • 中国知网(CNKI)
  • 西马戈
  • 乌尔里希的期刊目录
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 米亚尔
  • 科学索引服务 (SIS)
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Development, Characterization and Evaluation of Tinidazole Nanosuspension for Treatment of Amoebiasis

Pawar RN, Smita N Chavan and Menon MD

Amoebiasis is an infectious disease of gastrointestinal tract caused by the protozoan, Entamoeba histolytica. This disease is widely distributed worldwide and is endemic in most parts of India and other developing countries. The protozoa multiply rapidly in their hosts. Since effective vaccines are as yet unavailable, chemotherapy is the major strategy to treat infected individuals and reduce transmission. Nitroimmidazoles, like Tinidazole (TNZ) form an important class of drugs, which are active against both intestinal and systemic forms of amoebiasis. Most of these drugs have high dose and metallic to bitter taste which result in poor patient compliance. In the present study, nanosuspension was developed by nanoprecipitation method for oral delivery using Tinidazole as model drugs with improved its dissolution rate and hence bioavailability. With improved bioavailability it may be possible to reduce the dose requirement, which would be especially advantageous for paediatric patients. Ex-vivo absorption studies performed using the rat intestinal model showed an enhanced absorption from the nanosuspension as compared to micronized drug.